{"id":1019304,"date":"2026-11-10T07:22:49","date_gmt":"2026-11-10T12:22:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/"},"modified":"2026-11-10T07:22:49","modified_gmt":"2026-11-10T12:22:49","slug":"kailera-therapeutics-to-present-at-obesityweek-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/","title":{"rendered":"Kailera Therapeutics to Present at ObesityWeek 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrum<\/em>\n        <\/li>\n<li>\n          <em>Real-world obesity management presentation highlights the clinical unmet needs of people living with obesity <\/em>\n        <\/li>\n<\/ul>\n<p>WALTHAM, Mass., Nov.  10, 2026  (GLOBE NEWSWIRE) &#8212; Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that new clinical and real-world research will be presented at ObesityWeek 2026, taking place November 14-17 in Washington, D.C. The research includes the design of the Phase 3 KaiNETIC trials evaluating ribupatide injection, alongside analyses examining real-world obesity management and clinical needs among people living with obesity.<\/p>\n<p>\u201cPeople living with obesity have diverse and often highly individualized treatment needs, underscoring the importance of developing new therapeutic options,\u201d said Scott Wasserman, M.D., Chief Medical Officer of Kailera Therapeutics. \u201cThe research we are presenting at ObesityWeek reflects both the rigor of our clinical development program and our focus on better understanding the real-world obesity landscape and how our differentiated GLP-1-based pipeline can address unmet patient needs.\u201d<\/p>\n<p>\n        <strong><br \/>\n          <u>ObesityWeek 2026 Presentations<\/u><br \/>\n        <\/strong>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:65%;width:65%;min-width:65%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong><br \/>\n              <u>Title<\/u><br \/>\n            <\/strong>\n          <\/td>\n<td style=\"max-width:20%;width:20%;min-width:20%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong><br \/>\n              <u>Presenter<\/u><br \/>\n            <\/strong>\n          <\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong><br \/>\n              <u>Date<\/u><br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Rationale and design of the KaiNETIC-1 and -2 trials of ribupatide in people living with obesity<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Dr. Vanita Aroda<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">November 15<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Rationale and design of the KaiNETIC-3 trial of ribupatide in people with obesity and no diabetes<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Dr. Ildiko Lingvay<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">November 15<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Natural history and real-world effectiveness of obesity management medications: REFLECT design\/methods<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Briain O Hartaigh, Kailera<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">November 16<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Quantifying the Clinical Unmet Need in Adults with Class II and III Obesity in the United States<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Molly Plotkin, Kailera<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">November 16<\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>In addition, Hengrui Pharma will present findings from its Phase 3 HARBOR clinical program evaluating safiglipron (KAI-7535, HRS-7535), an investigational oral small-molecule GLP-1 receptor agonist. Safiglipron is being developed by Kailera Therapeutics outside Greater China.<\/p>\n<p>\n        <strong>Additional Presentations by Hengrui Pharma at ObesityWeek 2026<\/strong>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:85%;width:85%;min-width:85%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong><br \/>\n              <u>Title<\/u><br \/>\n            <\/strong>\n          <\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong><br \/>\n              <u>Date<\/u><br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">HRS-7535 for Weight Management in Chinese Adults with Overweight or Obesity: Phase 3 HARBOR-1 Study<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">November 15<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">HRS-7535 Effect on Glycaemic Status in Prediabetes: HARBOR-1 Subgroup Analysis<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">November 15<\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>All presentations will be accessible on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=980edB8KkRnLcZSfG7TFieiabNVzUJGusosu5sgPdZAQGTCfgPeP8a_Tx1uRWp9KDUys4mPx4Dufi7nISuiT6ndynMCTeYRCYZvH44FTALzv3ILqJiLzui-ca8i1lzl8\" rel=\"nofollow\" target=\"_blank\">Scientific Publications<\/a> section of the Kailera website following the congress. Additional information can be found on the ObesityWeek <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KCEmgsZceCcdEM4C5lDbR_ZCRVXMf4_PN-26LGNOadwPLbxNkzijsk6c7iKcSK_7Ea-PfP-5UoDrws7FSQe7cQ==\" rel=\"nofollow\" target=\"_blank\">website<\/a>.<\/p>\n<p>\n        <strong>About Ribupatide<\/strong><br \/>\n        <br \/>Ribupatide is a GLP-1 (glucagon-like peptide-1)\/GIP (glucose-dependent insulinotropic polypeptide) receptor dual agonist peptide being developed as a once-weekly subcutaneous injection and as a once-daily oral pill for the treatment of obesity and overweight.<\/p>\n<p>Once-weekly ribupatide injection has been studied in more than 3,000 clinical trial participants who have been dosed with treatment out to 52 weeks, including in multiple late-stage clinical trials conducted by Hengrui in China. Hengrui submitted an NDA to the National Medical Products Administration (NMPA) in China for long-term weight management in adults. In May 2024, Hengrui granted Kailera exclusive global rights outside Greater China to develop, manufacture and commercialize its portfolio of innovative GLP-1 therapeutics, including ribupatide injection and ribupatide oral. Kailera is currently evaluating ribupatide injection for the treatment of obesity in the KaiNETIC global Phase 3 clinical program.<\/p>\n<p>Based on compelling clinical data to date, Hengrui is advancing once-daily ribupatide oral to Phase 3 clinical trials in China, and Kailera plans to initiate global Phase 3 trials in obesity in the first half of 2027.<\/p>\n<p>\n        <strong>About Kailera Therapeutics<\/strong>\n      <\/p>\n<p>Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1\/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of safiglipron (also known as KAI-7535), a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1\/GIP\/glucagon receptor tri-agonist. Kailera\u2019s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=imcubWRmPALL2t3bHVEXR4FV71PsjGYvuwMIB4_TEn40RUYAPrg81AcDIDA06x2rE40P2_-Vga-91XIhujz16KjLjCKQvS1CEGYeD4EdWkTkU3Uw-LLN8z3EgclhwGUXItk8-xJJH1bd34pTOPLcB2eb2x_4b89xVkgglZAgsAJcBp67EQsNcGdxQynQiXAZ64cvn2j_i4dPjdlADxdxbxevBXCblw21tG-pW7Ox6QQoBQ3nuBkbvJcSe4gRfvjjlVYwuRdKUQFrvLmHtU3MEAR0ti-QZjuGpbB12pgOcYNIJIm_xUuam3X2j554BtAetJeP3Ke-TxjxK5Eu-MVhSY39fBwOzmvB8qbm1OIXnZDPRhQZBxIDlN44SpsDFdpXZuA_amiLCy3bSevJq3B_BE2hGF1CLIz8rrf5OaklFBUbWjTea5KnwDbWJ0VJXzQXNJWLXSba1DQZeHkctxyMSErMDHbAZlzt4Zq5VkYGPWD8tiPhaXLuDL5Zvbv-nVga4Xde3KaD5ntVPpGFdOV6LVJ87y05W-Z-8SAB1j2xBpAQxe4pNqcPOojc3X5Xc-cOogMPJDHX9fmCrYOIhTDPDxWrqFEpkrl9nPHfW7MV-TWp8NiH096kIr1VhyVRelD4dhNikodMFg3CttvOpTkMJbQdrQKAGldqjQiwFzDFXhjLI4NDVY7FwuwmHB0rMDLeukOaeRZ4gqSWfNHcXRsmgbg4gqsUgC7NuSjw5AOTBEn-5KSASt4-Y32kPyaNTM2qJ9XYbsAnSqRUIq6Rnc9F3w==\" rel=\"nofollow\" target=\"_blank\">www.kailera.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mALFoL7B4_uMblfAjOIYpPllh_WcSNZxxXy7SIUrCX4hUIhaeq9Tetcn0xNu1yl92eAMcMvlctHsQT_7W5nJqC-NNUbrYG4ChQF9xCt5d-yNxj5UmD8YbTmWVAnu9p1G8rQWzyK9XhFhbYuaY_C1-7BhFlYrsgdCwOuimYKbJ9UTz-YFDIBLrveSGXJ90p5ncz656B7n5cdaBC5CzwVw55qJYYUqa7kg-P8o9VLGaF6gOxtFxauisljmMu01G__LKmJ-Wwb1HO3q-MzGjnDn7_PqFy-tgEl00v3YhvVBu1msxUUHreV0TTdR0ryWTWEfwms2DScJsTr2eYZ9KY3HdAdswz2FTa-9RwTeRdLrKUggMO5hSLOAkWIDSNtv5RmwgdV4HgZXkOKWdGRETLsYsPH4qB7fs9OPBQsLu3lYVey500V_25IZ1wmvr-3e2j4xpfUvA9eBHDSSynLg0qQ1YhYRxDJUByVjjcu4_weCY5P3afUnyD8-5louVTl3sce3g9dpmnMk3UKQLmmz5yphCTT-2GNrEi5WLRXvjKm_YEKzmHOhu6GeRtXb1DTF8HBHkegT4s-vv0WCw6eL1dezNNWG70ZPzoLeajM5QY85rvKZ0A-TRklVycopbNr9uCftudMDVPp-1AkWfK76pFK60Utbs5cvh01k__MbshKrP_m4UmKSy1-SRSVKnYDguMSw\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xxm-xTbVywkSnsJIykOgjW1YflK5ZAI-D5khH64DHWnPhvVL4jIVKyBCXLl3y9xpfl2esB27oF5fhdwkqfV2CSvSNMlTb-50HTKw_uWcWFtAiijOWVT6bork1ZnUgXJrj9IbW5DSin3uQCSsnNwGgScWoM9cpQOjCBs1yF-mrWZSYEVfdkFJTpQZ4MFBQ7FKhbPE8riEYwKemU4pzdBOkQ277OB9rmNBx1TKdZ1gsQPbZItqKswkn4EDy9x_9ZtYtmbtHnpMfB1tY-si4mxFxGfu-WJa_UVjZQtB-u-k1mW3t__GgfqzIMIOtH6aJDdhEXjVV3vHdSJHz4hBjlwacbDnC7UNdRfILId552UhoFuFzaKJsT4m-NXsrl_g7X1LX5f_9Iwe4AOHGb8y3OXSCNw8fOXnjmOlZPUfyHu6mEjBYNdNQ0Pq-Y5ZlZNgRE5thnKOwZA2FXAWIhwGORQxuIDTHRuusnNvcsmf3RtZWUR3VS_mVNXl08yfC3SdVbP-SY_pizdrU5ncLCUeYaw1tjWNGAuGJk2M8K29FAUfBrpeO2-32A6VIFnRYkfL3mUIYInZIiwsT-dddytmt61PRIAQc_rdBti6BTgVIuXaZDA=\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Special Note Regarding Kailera Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera\u2019s portfolio, the timing, design and outcome of research and development activities, including with respect to the timing of initiation and completion of clinical trials and the design and goals of clinical trials, market opportunities for product candidates, the competitive landscape, and participation in upcoming events. Forward-looking statements can be identified by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; \u201csuggest,\u201d &#8220;plan,&#8221; \u201cgoal,\u201d \u201cvision,\u201d &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption \u201cRisk Factors\u201d in Kailera\u2019s filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.<\/p>\n<p>\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p>Maura Gavaghan<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FoZQJa67t-4TEvcd7BpVeQ1k5cNrulDuHG7cNkt5i32BmVKetMSlgc0AZfPERVR-0lMs7vPhtqK_jwliEFCH6Bk_eFYYyj7kcprlMPzoc8ydoD4i3O5BPPoInS1kri_tnG3VkLi6Wp4L2sEEP6p8_TiJ4O_L1MEnSKa1YrabvPui90iY2_90_NfcDUhmHeqRWqAzmwWR_Xb1AC25GMSRVDsN5T21SjDgQNp6nGu09N8FZj6JBGx83b5Rp2bVxvxi4hO0PklCfQja4uUrtBbo0kega2KarL5FQbyGGaImqRkHioQ1XGN06kyGT8f84RDUgtvp1FSixBA0joXMqWmw9Wqf1RKQGUbrmZ8LXSyq11vicH7hBT2YK6tnTVV0aTuMFXm5M-lAF8vYcB-Gh_SMrjr_AsFwt2IX6zO4knWTtskEP9Oyyk2b8TbfpErX2q_-sXqTmQIY5cv3IfWeeQt3dVTrSi7pkuZcBvyWXOklsjhsqS_PgcwYHVi2T1GWL3ouhUsdJOrauu-YbC_oFOiQHVmGDO25MEig_Muwnp2K4lwiI2E3KPv2ISMBXBVAuWyP\" rel=\"nofollow\" target=\"_blank\">maura.gavaghan@kailera.com<\/a><\/p>\n<p>Anna Robinson<br \/>Vice President, Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RmVBUemQNSu0GhrUjgLIkqsW_l7vyRqYeCt7G70fpwJ_C0Sk5mhs7JqnqlTCdfrISn64XjqJ1dtf25fKkgnxcdgy6cGUTlXUEMVP3RACtqv-S9h1pH-doYgDqJEGvcV4NUgavrKNPN705vQePvhiM3skuiLmUv19-cms0ZWEAqLvYA-jLNM-XudFfF2ihAS6h9n1nZQs4IZCZgGEZpQ0m8XuPFsQBKE3n5CxMfoSedSLVJFA9NNxrOfShye4LNnoHFW_MF2fzC9_3UAVQ8o3Gz70J65ouPp-Z0ZFcQ3QF1EN_6M8OVwldkmhEGhrD-DkA36tfrQ3P7VuOGDQNNTu4FNJml7uAPTVhEpPLodOpsohAF3iarpdpki2eu6b7aa3TdfLaH2L9A-4ZZv8R071iTJuSDTwsyKRZq3tbWpzGuFY_gyzEC5YtZ0WrE6c3F-lJWANHUXMKlPoNtwoBOT-FbUEifi8qqipkMEuIijVd_k-I_IEYF_jhi1m0yqL5MX7GChDx5q4kHY6sg2uWwRrMQ==\" rel=\"nofollow\" target=\"_blank\">anna.robinson@kailera.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDAxMiM3OTU2Mjc4IzIyOTUyMTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTk3MGM4MjQtY2Q0Zi00YWFiLWE3OGQtYTk0NzY0MjIxYzFkLTEzMDY3NjItMjAyNi0xMS0xMC1lbg==\/tiny\/Kailera-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrum Real-world obesity management presentation highlights the clinical unmet needs of people living with obesity WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that new clinical and real-world research will be presented at ObesityWeek 2026, taking place November 14-17 in Washington, D.C. The research includes the design of the Phase 3 KaiNETIC trials evaluating ribupatide injection, alongside analyses examining real-world obesity management and clinical needs among people living with obesity. \u201cPeople living with obesity have diverse and often highly individualized treatment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kailera Therapeutics to Present at ObesityWeek 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1019304","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kailera Therapeutics to Present at ObesityWeek 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kailera Therapeutics to Present at ObesityWeek 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrum Real-world obesity management presentation highlights the clinical unmet needs of people living with obesity WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that new clinical and real-world research will be presented at ObesityWeek 2026, taking place November 14-17 in Washington, D.C. The research includes the design of the Phase 3 KaiNETIC trials evaluating ribupatide injection, alongside analyses examining real-world obesity management and clinical needs among people living with obesity. \u201cPeople living with obesity have diverse and often highly individualized treatment &hellip; Continue reading &quot;Kailera Therapeutics to Present at ObesityWeek 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-10T12:22:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDAxMiM3OTU2Mjc4IzIyOTUyMTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kailera Therapeutics to Present at ObesityWeek 2026\",\"datePublished\":\"2026-11-10T12:22:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/\"},\"wordCount\":1090,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDAxMiM3OTU2Mjc4IzIyOTUyMTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/\",\"name\":\"Kailera Therapeutics to Present at ObesityWeek 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDAxMiM3OTU2Mjc4IzIyOTUyMTI=\",\"datePublished\":\"2026-11-10T12:22:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDAxMiM3OTU2Mjc4IzIyOTUyMTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDAxMiM3OTU2Mjc4IzIyOTUyMTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kailera-therapeutics-to-present-at-obesityweek-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kailera Therapeutics to Present at ObesityWeek 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kailera Therapeutics to Present at ObesityWeek 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/","og_locale":"en_US","og_type":"article","og_title":"Kailera Therapeutics to Present at ObesityWeek 2026 - Market Newsdesk","og_description":"Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrum Real-world obesity management presentation highlights the clinical unmet needs of people living with obesity WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that new clinical and real-world research will be presented at ObesityWeek 2026, taking place November 14-17 in Washington, D.C. The research includes the design of the Phase 3 KaiNETIC trials evaluating ribupatide injection, alongside analyses examining real-world obesity management and clinical needs among people living with obesity. \u201cPeople living with obesity have diverse and often highly individualized treatment &hellip; Continue reading \"Kailera Therapeutics to Present at ObesityWeek 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-10T12:22:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDAxMiM3OTU2Mjc4IzIyOTUyMTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kailera Therapeutics to Present at ObesityWeek 2026","datePublished":"2026-11-10T12:22:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/"},"wordCount":1090,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDAxMiM3OTU2Mjc4IzIyOTUyMTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/","name":"Kailera Therapeutics to Present at ObesityWeek 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDAxMiM3OTU2Mjc4IzIyOTUyMTI=","datePublished":"2026-11-10T12:22:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDAxMiM3OTU2Mjc4IzIyOTUyMTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDAxMiM3OTU2Mjc4IzIyOTUyMTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kailera-therapeutics-to-present-at-obesityweek-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kailera Therapeutics to Present at ObesityWeek 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1019304"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019304\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1019304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1019304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1019304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}